trimetrexate has been researched along with Cancer of Intestines in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The base model employed for modeling dose-response effect is the four parameter Hill equation [1]." | 1.32 | A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example. ( Brun, Y; Greco, WR; Slocum, HK; White, DB; Wrzosek, C, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| White, DB | 1 |
| Slocum, HK | 1 |
| Brun, Y | 1 |
| Wrzosek, C | 1 |
| Greco, WR | 1 |
1 other study available for trimetrexate and Cancer of Intestines
| Article | Year |
|---|---|
A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example.
Topics: Adenocarcinoma; Algorithms; Antimetabolites; Antineoplastic Agents; Cell Division; Cell Line, Tumor; | 2003 |